Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(20%)
Results Posted
100%(3 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_4
1
20%
Ph phase_3
3
60%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
3(75.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 33 (75.0%)
Phase 41 (25.0%)

Trials by Status

completed360%
recruiting120%
terminated120%

Recent Activity

1 active trials
Showing 5 of 5
completedphase_3

Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

NCT04508530
completedphase_3

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

NCT04502030
recruitingphase_3

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

NCT04929236
terminatedphase_4

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

NCT03866798
completed

Non-Interventional Study on the Tolerability and Efficacy of IVIG

NCT02303093

Clinical Trials (5)

Showing 5 of 5 trials
NCT04508530Phase 3

Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

Completed
NCT04502030Phase 3

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Completed
NCT04929236Phase 3

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Recruiting
NCT03866798Phase 4

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

Terminated
NCT02303093

Non-Interventional Study on the Tolerability and Efficacy of IVIG

Completed

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5